Cbd on drug test
Pro Research Analysisby 
Searched over 200M research papers
The Impact of CBD on Drug Tests: Key Insights
CBD and Oral Fluid Drug Tests
Orally Administered CBD and False Positives
One of the primary concerns for CBD users is whether CBD can cause false positives for THC in drug tests. A study investigated this by administering different doses of pure CBD (15 mg, 300 mg, and 1500 mg) to participants and then testing their oral fluid using two standard point-of-collection (POC) devices: the DrugWipe® 5S and the Dräger DrugTest® 5000. The results showed that none of the participants tested positive for THC, indicating that orally administered CBD does not produce false-positive results for THC on these devices1.
CBD and Urine Drug Tests
Urinary Pharmacokinetic Profile of CBD
Another study focused on the urinary pharmacokinetic profile of CBD following both oral and vaporized administration. The study found that pure CBD, whether ingested orally or vaporized, did not result in positive urine drug tests for THC-COOH, the primary metabolite tested in standard urine drug screens. Only one out of 218 urine specimens screened positive at the lowest immunoassay cutoff (20 ng/mL), and none exceeded the confirmatory cutoff of 15 ng/mL2.
Impact of CBD-Dominant Cannabis
However, the study also highlighted that CBD products containing even small amounts of THC could lead to positive urine drug tests. When participants inhaled vaporized CBD-dominant cannabis (containing 3.7 mg of THC), several urine samples tested positive for THC-COOH, emphasizing the importance of accurate labeling and regulation of THC content in CBD products to prevent unexpected positive drug tests2.
Conversion of CBD Metabolites
Potential for False Positives in Laboratory Conditions
A third study explored whether the CBD metabolite 7-carboxy-cannabidiol (7-COOH-CBD) could convert to THC-COOH during sample preparation, potentially causing false positives. The study found that 7-COOH-CBD did not react in immunoassay screenings and did not convert to THC-COOH under standard testing conditions. However, conversion was observed when samples were exposed to acidic conditions for extended periods or when specific derivatization techniques were used, suggesting that while unlikely, certain laboratory conditions could potentially lead to false positives3.
Conclusion
In summary, pure CBD, whether administered orally or vaporized, does not typically result in positive drug tests for THC using standard testing methods. However, CBD products containing even trace amounts of THC can lead to positive results, underscoring the need for accurate product labeling. Additionally, while standard testing conditions do not convert CBD metabolites to THC-COOH, specific laboratory conditions might, although this is rare. Users of CBD products should be aware of these nuances to avoid unintended positive drug tests.
Sources and full results
Most relevant research papers on this topic
Orally administered cannabidiol does not produce false‐positive tests for Δ9‐tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000
Orally administered CBD does not produce false-positive tests for THC on standard oral fluid testing devices, reducing the likelihood of being falsely accused of DUIC.
RCTUrinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis.
Acute dosing of pure CBD will not result in a positive urine drug test, but CBD products that also contain 9-THC may produce positive urine results.
RCTConversion of 7-Carboxy-Cannabidiol (7-COOH-CBD) to 11-nor-9-Carboxy-Tetrahydrocannabinol (THC-COOH) During Sample Preparation for GC-MS Analysis.
7-COOH-CBD does not produce false positive results for THC-COOH in urine drug testing, but may convert to THC-COOH under certain conditions.
Prevalence of Cannabidiol, Δ9- and Δ8-Tetrahydrocannabinol and Metabolites in Workplace Drug Testing Urine Specimens.
Cannabidiol (CBD) is prevalent in workplace drug testing urine specimens, with 8-THC-COOH being found in 76 (1.3%) specimens, suggesting use of 8-THC-containing products in some cases.
Observational StudyAbuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial
Cannabidiol (CBD) has low abuse potential compared to alprazolam and dronabinol, with no significant cognitive or psychomotor effects.
RCT
Highly CitedUrinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Urinary CBD concentrations are higher after oral administration compared to vaporized CBD, and hemp products containing low amounts of 9-THC may produce a cannabis-positive urine drug test.
Observational StudyDetection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices
POCT devices can detect recent cannabis use, but limitations should be noted and confirmatory LC-MS/MS quantification is strongly advisable for more accurate results.
RCTQuantitative determination of CBD and THC and their acid precursors in confiscated cannabis samples by HPLC-DAD.
This HPLC-DAD method accurately quantifies CBD and THC in confiscated cannabis samples, making it suitable for routine potency testing in forensic settings.
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease
Acute CBD administration at a dose of 300 mg decreased anxiety and tremor amplitude in patients with Parkinson's disease.
RCT
Very Rigorous JournalHighly CitedOral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.
Oral cannabidiol does not show any signals of abuse liability at the doses tested in frequent marijuana smokers, potentially informing regulatory decisions regarding its Schedule I status on the CSA.
RCTHighly Cited